Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

interferon alfacon 1 (Discontinued)Brand and Other Names:Infergen

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 9mcg/0.3mL
  • 15mcg/0.5mL
more...

Chronic Hepatitis C

This product was discontinued in September 2013

9 mcg SC 3 times/week for 24 wk

Retreatment: Allow 48 hr between doses

If severe toxicity occurs: Reduce to 7.5 mcg SC 3 times/week or discontinue

Monitor: Hgb, WBC, Plt, LFTs, creatinine, thyroid

Combination use with ribavirin

  • Retreatment: 15 mcg SC with ribavirin qDay for up to 48 weeks
  • <75 kg: ribavirin 1 g PO divided q12hr
  • ≥75 kg: ribavirin 1.2 g PO divided q12hr
  • Monitor: Hgb, WBC, Plt, LFTs, creatinine, thyroid

Renal Impairment

CrCl <50 mL/min: Avoid combination therapy with ribavirin in hepatitis C treatment

Hepatic Impairment

Moderate-to-severe (Child-Pugh Class B and C): Contraindicated

Other Indications & Uses

Off-label: Hairy-cell leukemia (in combination with G-CSF)

Safety and efficacy not established

Next

Interactions

Interaction Checker

interferon alfacon 1 and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Headache (~80%)

            Fatigue (~70%)

            Fever (~60%)

            Rigors (~60%)

            Myalgia (~55%)

            Body pain (~50%)

            Arthralgia (~45%)

            Back pain (29-42%)

            Granulocytopenia (23-42%)

            Abd pain (24-41%)

            Nausea (30-40%)

            Insomnia (24-39%)

            Pharyngitis (17-34%)

            Nervousness (16-31%)

            URI (16-31%)

            Leukopenia (15-28%)

            Limb pain (13-26%)

            Diarrhea (~25%)

            Cough (12-22%)

            Dyspepsia (12-21%)

            Anorexia (~20%)

            Depression (~20%)

            Inj site erythema (~20%)

            Anxiety (19%)

            Thrombocytopenia (19%)

            Alopecia (14%)

            Pruritus (14%)

            Skeletal pain (14%)

            Rash (13%)

            Rhinitis (13%)

            Chest pain (5-13%)

            Hot flushes (4-13%)

            Vomiting (12%)

            Inj site pain (8-11%)

            Asthenia (~10%)

            1-10% (selected)

            Abnormal LFTs

            Amnesia

            Constipation

            Dysmenorrhea

            Libido decrease

            Bronchitis

            Epistaxis

            Hypertension

            Palpitations

            Vaginitis

            Frequency Not Defined

            Vision loss or retinopathy

            Previous
            Next

            Warnings

            Black Box Warnings

            Alfa interferons cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders

            Monitor closely with periodic clinical and laboratory evaluations

            Avoid use in history of autoimmune disorders

            May cause or worsen fatal of life-threatening ischemic or infectious disorders

            Discontinue drug if persistently severe or worsening signs or symptoms of the above conditions are present; disorders typically resolve after stopping therapy

            Use with ribavirin

            • Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and in partners of male patients
            • Ribavirin causes hemolytic anemia which may exacerbate cardiac disease
            • Ribavirin is a potential carcinogen
            • Combination therapy may be carcinogenic

            Contraindications

            Hypersensitivity to drug or any other component

            Decompensated hepatic disease

            Autoimmune hepatitis

            Additional contraindications when used with ribavirin

            • Pregnant women
            • Men whose female partners are pregnant
            • Hemoglobinopathies (eg, thalassemia major, sickle-cell anemia)
            • CrCl <50 mL/min

            Cautions

            History of endocrine disorder, pre-existing cardiac disease

            May worsen depression and cause suicidal ideation

            Discontinue if new or worsening visual disorder

            Advise patients to use contraception

            Suspend if signs suggestive of pancreatitis

            Discontinue if pancreatitis or colitis develops

            Discontinue if severe myelosuppression develops

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C (interferon monotherapy); X (combination with ribavirin)

            Lactation: not known if excreted in breast milk, use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Immunomodulating cytokine; may interfere with oncogene expression, induce gene transcription, may alter cellular differentiation and cell surface antigen expression , may increase phagocytic activity of macrophages, may inhibit cell growth; may increase phagocytic activity of macrophages and increase cytotoxicity effects of lymphocytes for target

            Pharmacokinetics

            Peak Plasma Time: 24-36 hr (healthy volunteers)

            Previous
            Next

            Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.